Company news

Ocular Therapeutix, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

November 2, 2026

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

October 29, 2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 9, 2026

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

October 1, 2026

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

September 15, 2026

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

September 1, 2026

Ocular Therapeutix trade; Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 13, 2026

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

August 3, 2026

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

June 17, 2026

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

June 3, 2026

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

May 5, 2026

Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD

April 30, 2026

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

April 29, 2026

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

April 28, 2026

Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences

April 27, 2026

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

April 22, 2026

Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

April 15, 2026

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

April 12, 2026

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

March 31, 2026

Ocular Therapeutix™ to Participate in March Investor Conferences

February 23, 2026

Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

February 22, 2026

Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

February 17, 2026

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

February 13, 2026

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

February 4, 2026

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 23, 2026

Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

January 20, 2026

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD

December 7, 2025

Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR

November 23, 2025

Ocular Therapeutix™ to Participate in November and December Investor Conferences

November 11, 2025

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

November 3, 2025

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

November 3, 2025

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025

October 27, 2025

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

October 6, 2025

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

September 29, 2025

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

September 29, 2025

Ocular Therapeutix™ to Host Investor Day on September 30, 2025

September 7, 2025

Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences

August 26, 2025

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR

August 11, 2025

Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights

August 4, 2025

Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025

July 28, 2025

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

June 25, 2025

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

June 15, 2025

Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration

May 27, 2025

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

May 13, 2025

Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

May 4, 2025

Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

April 28, 2025

Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

April 27, 2025

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

March 30, 2025

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

March 2, 2025

Ocular Therapeutix™ to Present at Two Investor Conferences in March

February 24, 2025

Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.